ea0103p122 | Miscellaneous/Other 2 | BSPED2024
Malhotra Neha
, Yan Georgina
, Morgan Kate
, Gilbert Clare
, Gan Chin
, Dastamani Antonia
Background: Lanreotide, a prolonged-release somatostatin analogue, has been used off-label for nearly a decade to treat congenital hyperinsulinism (CHI) cases resistant to diazoxide. Lanreotides side-effects include diarrhea, topical allergic reactions, hepatitis, gallstones, growth suppression, hypothyroidism, and gastrointestinal dysmotility. However, there are limited case reports documenting its safety in infants with CHI.Objective: To evaluate...